## Rationale In a medically inoperable patient with early-stage, low-to-intermediate risk endometrial cancer, **progestin therapy** is the standard non-surgical alternative, particularly when the tumor is confined to the inner myometrium and grade 1–2 histology. ### Key Points: **Why progestin therapy is appropriate:** - Grade 1–2 endometrioid carcinomas are hormone-responsive tumors - Progestins (megestrol acetate 160 mg/day or medroxyprogesterone acetate 500 mg/day IM weekly) achieve response rates of 50–70% in early-stage disease - FIGO stage IB with inner myometrial invasion carries lower risk of extrauterine spread - Preserves fertility potential (though patient is 45 and nulliparous; fertility preservation may be considered) - Requires serial endometrial biopsies at 3–6 months to assess response - If no response or progression, then reassess surgical candidacy or consider radiation **Clinical Pearl:** Progestin therapy is NOT first-line for high-grade (grade 3) or non-endometrioid histologies (serous, clear cell), which are inherently progestin-resistant. **High-Yield Fact:** The GOG-99 trial demonstrated that adjuvant vaginal brachytherapy alone (without chemotherapy) is adequate for stage IB, grade 1–2 endometrial cancer in surgically treated patients. However, in the medically inoperable setting, progestin therapy is preferred as the initial approach. ## Comparison Table | Modality | Indication | Medically Inoperable? | |----------|-----------|----------------------| | Progestin | Grade 1–2, stage IA–IB, endometrioid | Yes (preferred) | | Radiation | Adjuvant (post-op) or primary in inoperable | Yes (if progestin fails) | | Chemotherapy | High-grade, non-endometrioid, stage III–IV | Not for early-stage | | Surgery | All operable cases (gold standard) | No |
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.